The global gene therapy market was valued at USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, growing at a robust compound annual growth rate (CAGR) of 33.6%. In 2019, the United States led the global landscape, accounting for 59.83% of the total market share.
The gene therapy market is emerging as a transformative force in modern medicine, offering the potential to treat or even cure a wide range of genetic and chronic diseases. By targeting the underlying genetic causes of disorders, gene therapy provides a more precise and long-lasting therapeutic approach compared to traditional treatments. The market is being driven by advancements in gene editing technologies, increasing R&D investments, and a growing number of regulatory approvals for novel therapies. With expanding applications in oncology, rare genetic conditions, and neurology, the gene therapy market is gaining significant traction. Despite challenges such as high costs, regulatory complexity, and manufacturing hurdles, the future of the gene therapy market appears promising, fueled by ongoing innovation and global healthcare demand.
Continue reading for more details:
https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243
Market Segmentation
The gene therapy market is segmented by therapy type, including somatic gene therapy and germline gene therapy.
By vector type, the market includes viral vectors (lentivirus, adeno-associated virus, retrovirus) and non-viral vectors (naked DNA, liposomes).
Based on indication, the gene therapy market covers oncology, genetic disorders, cardiovascular diseases, neurological disorders, and infectious diseases.
By delivery method, the market is segmented into in vivo and ex vivo gene therapies.
The gene therapy market also segments by end-users, including hospitals, specialty clinics, and academic & research institutes.
List Of Key Companies Profiled in Gene Therapy Market:
Novartis AG
Spark Therapeutics, Inc.
Biogen
Gilead Sciences, Inc
Amgen, Inc.
Jazz Pharmaceuticals, Inc.
Sarepta Therapeutics
GlaxoSmithKline plc
Other Prominent Players
Market Growth
The gene therapy market is witnessing substantial growth due to the increasing prevalence of genetic disorders and rare diseases.
Advancements in genome editing technologies such as CRISPR and viral vector development are accelerating progress in the gene therapy market.
Rising approvals of gene therapy products and supportive regulatory pathways are creating a favorable environment for market expansion.
Growing investments from pharmaceutical and biotechnology companies are fueling innovation in the gene therapy market.
Increased awareness of precision medicine and the potential for curative treatments is boosting demand in the gene therapy market.
Restraining Factors
High development and treatment costs limit widespread adoption in the gene therapy market.
Complex manufacturing processes and supply chain challenges present barriers to scalability.
Regulatory hurdles and lengthy approval timelines can delay market entry for new gene therapies.
Safety concerns such as immune reactions or off-target effects pose risks to patient outcomes in the gene therapy market.
Limited infrastructure and skilled professionals in emerging regions hinder clinical adoption of gene therapies.
Regional Analysis
North America leads the gene therapy market, driven by strong R&D capabilities, early adoption of advanced treatments, and favorable regulatory frameworks.
Europe is a significant contributor, with increasing clinical trials and government support for gene-based innovations.
Asia Pacific is expected to experience the fastest growth in the gene therapy market, supported by a large patient population, rising biotech investments, and expanding healthcare access.
Latin America is gradually emerging as a potential market due to growing interest in advanced therapies and improving regulatory standards.
The Middle East & Africa region is showing steady progress in the gene therapy market, with efforts to enhance healthcare infrastructure and increase access to innovative treatments.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free)
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com